Abst rac t Objective: Challenge tests designed to evaluate serotoninergic pathways have widely used intravenous citalopram. Oral citalopram has also been used, but unsatisfactory results were obtained with a dose of 20 mg. The objective of this study was to determine whether a higher oral dose would reproduce similar to those described for intravenous administration. To that end, we evaluated c...

Background: Menopause is a critical and sensitive period and has a common symptom of vasomotor signs, psychologic changes and sleep disorders. With regarding the citalopram complications and effects of Iranian herbs, the aim of this study was to compared the therapeutic effect of the combination of area part of Melissa officinalis and fennel fruits extract with Nigella sativa powder with citalo...

an 80-year-old man developed nightmares while using citalopram for mild depression. during the first two weeks of treatment with citalopram (10 mg daily), he didn’t experience any adverse reactions. after two weeks, he developed nightmaresand vivid dreams that were repeated every night and awakened him in midnight. although the signs of depression were relatively disappeared, the patient was an...

BACKGROUND Citalopram is the most commonly prescribed antidepressant in Canada. Concerns have been raised about its cardiac safety, and a dose-dependent prolongation of the QT interval has been documented. Drug interactions involving concomitant use of other medications that prolong the QT interval or increase citalopram levels by interfering with its metabolism increase the cardiac risk. Regul...

AIMS An open, controlled, randomized, crossover study was conducted in healthy males to assess the possible occurrence of a pharmacokinetic/pharmacodynamic interaction between warfarin and the selective serotonin re-uptake inhibitor citalopram. METHODS Twelve subjects received a single 25 mg dose of racemic warfarin either alone or on Day 15 of a 21-day oral dosing regimen of 40 mg citalopram...

OBJECTIVE Citalopram has been shown to improve agitation in patients with Alzheimer's disease. The authors evaluated whether other neuropsychiatric symptoms improve with citalopram treatment compared with placebo. METHOD In this planned secondary analysis of the Citalopram for Agitation in Alzheimer's Disease study, the authors evaluated the effect of citalopram on the 12 neuropsychiatric sym...

INTRODUCTION Abnormal movements such as acute dystonia, dyskinesia, parkinsonism, exacerbation of Parkinson disease, akathisia and possibly neuroleptic malignant syndrome may be associated with the use of selective serotonin reuptake inhibitors (SSRIs) rarely. Citalopram, a typical SSRI, used in serotonergic dysfunction related disorders, potentially can cause extrapyramidal symptoms such as ac...

The present study investigates the gastroprotective effect of citalopram, an antidepressant drug. Gastroprotective activity of citalopram (5, 10 and 20 mg/kg, bid, po) was evaluated both by single and 14 days repeated pretreatment in the cold restraint stress (CRS) model and 14 days repeated pretreatment in pyloric ligation (PL) model. In addition to ulcer scoring and its histological assessmen...

Citalopram is a serotonin-selective reuptake inhibitor (SSRI) widely used in the treatment of major depression and sometimes also anxiety-associated conditions, obsessive compulsive disorder and behavior disturbances associated with dementia [1, 2]. Citalopram is relatively well tolerated and has been considered to have comparatively low potential for drug–drug interactions and anti-adrenergic ...

According to both in vitro and in vivo data P-glycoprotein (P-gp) may restrict the uptake of several antidepressants into the brain, thus contributing to the poor success rate of current antidepressant therapies. The therapeutic activity of citalopram resides in the S-enantiomer, whereas the R-enantiomer is practically devoid of serotonin reuptake potency. To date, no in vivo data are available...